Celldex Therapeutics CLDX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's EPS (diluted)?
- Celldex Therapeutics (CLDX) reported EPS (diluted) of -$1.18 in Q1 2026.
- How has Celldex Therapeutics's EPS (diluted) changed year-over-year?
- Celldex Therapeutics's EPS (diluted) decreased by 45.7% year-over-year, from -$0.81 to -$1.18.
- What is the long-term trend for Celldex Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Celldex Therapeutics's EPS (diluted) has grown at a 24.2% compound annual growth rate (CAGR), from -$1.64 to -$3.90.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.